Literature DB >> 3276271

Antibiotic use during major head and neck surgery.

J T Johnson1, V L Yu.   

Abstract

The appropriate use of prophylactic antimicrobial therapy in patients undergoing major contaminated surgery is an important issue for the head and neck surgeon. A series of five sequential, prospective, randomized, double-blind clinical trials of antibiotics for patients undergoing major contaminated oncologic head and neck surgery are reviewed and summarized. The information generated from the study of these 547 patients indicates that a number of drugs or drug combinations have similar efficacy when employed in adequate dosage. The bacteriologic spectrum of the prophylactic drug should include oral microflora, especially anaerobic bacteria. The administration of antibiotics effective against gram-negative aerobic bacteria may be unnecessary. Perioperative antibiotic administration should be initiated prior to surgery. To date, no evidence exists to support prolonged administration of antibiotics beyond the first 24 hours following surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276271      PMCID: PMC1493244          DOI: 10.1097/00000658-198801000-00020

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  The effective period of preventive antibiotic action in experimental incisions and dermal lesions.

Authors:  J F Burke
Journal:  Surgery       Date:  1961-07       Impact factor: 3.982

2.  Prophylactic antibiotics in penetrating wounds of the abdomen.

Authors:  W D Fullen; J Hunt; W A Altemeier
Journal:  J Trauma       Date:  1972-04

3.  Cefoperazone as a prophylactic agent in abdominal hysterectomy.

Authors:  S A Gall; G Hill
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

4.  Comparative study of cefazolin, cefoxitin, and ceftizoxime for surgical prophylaxis in colo-rectal surgery.

Authors:  D G Maki; D R Aughey
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790

5.  Antibiotic prophylaxis in surgery for head and neck cancer. Comparative study of short and prolonged administration of carbenicillin.

Authors:  G Mombelli; L Coppens; P Dor; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

6.  Short-term cephalosporin prophylaxis in transurethral surgery.

Authors:  P Iversen; P O Madsen
Journal:  Clin Ther       Date:  1982       Impact factor: 3.393

7.  Antimicrobial prophylaxis for contaminated head and neck surgery.

Authors:  J T Johnson; E N Myers; P B Thearle; B A Sigler; V L Schramm
Journal:  Laryngoscope       Date:  1984-01       Impact factor: 3.325

8.  Comparison of cefamandole and cefazolin during cardiopulmonary bypass.

Authors:  C S Bryan; C W Smith; J P Sutton; W B Allen; R Blanding; J D Gangemi
Journal:  J Thorac Cardiovasc Surg       Date:  1983-08       Impact factor: 5.209

9.  Antimicrobial prophylaxis of infections in head and neck cancer surgery.

Authors:  M Piccart; P Dor; J Klastersky
Journal:  Scand J Infect Dis Suppl       Date:  1983

10.  Salivary scan after major ablative head and neck surgery with prediction of postoperative fistulization.

Authors:  R K Newman; F L Weiland; J T Johnson; P R Rosen; L W Gumerman
Journal:  Ann Otol Rhinol Laryngol       Date:  1983 Jul-Aug       Impact factor: 1.547

View more
  3 in total

1.  Prevention and Treatment of Postsurgical Head and Neck Infections.

Authors:  Rebecca Fraioli; Jonas T. Johnson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

2.  Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications.

Authors:  D Swanson; R A Maxwell; J T Johnson; R L Wagner; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

3.  Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin.

Authors:  M Phan; P Van der Auwera; G Andry; M Aoun; G Chantrain; R Deraemaecker; P Dor; D Daneau; P Ewalenko; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.